TICKERNERD
Menu
TRLVTRLVHealthcare · Drug Manufacturers - Specialty & Generic

TRLV Stock Forecast: Trulieve Cannabis Corp. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$8.60
−0.58% on the day

The 7 Wall Street analysts covering Trulieve Cannabis Corp. hold a median 12-month price target of $20 — +126.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.7B
Ticker Nerd rank
98 / 100
Median analyst target
$20
Analysts covering
7
Total return, dividends reinvested
1W
+3.2%
1M
−12.1%
YTD
−1.0%
1Y
+83.0%
From 52W high
−33.8%
From 52W low
+80.7%
$5
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TRLV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Trulieve Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
97
Accruals
95
Value
92
Issuance
87
Revisions
75
Momentum
70
Growth
61
Size
38
Volatility
20

Quality (97): The business earns solid, repeatable profits on what it owns.

Volatility (20): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Trulieve Cannabis Corp. — and when they’d sell — is the membership.

Wall Street

TRLV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRLV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26TRLVHigh $21Median $20Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $15Median $20High $21

The green dot is the last close — the median target sits +126.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 July 2026Cantor FitzgeraldInitiatesOverweight$15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TRLV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Trulieve Cannabis Corp. (TRLV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.2×

Cheaper than 95% of US stocks

Price / sales
1.4×

Cheaper than 62% of US stocks

Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
6.0×

Cheaper than 52% of US stocks

Growth & margins
Revenue growth (YoY)
−3.7%

Higher than 23% of US stocks

Earnings growth (YoY)
—
Gross margin
59.3%

Higher than 74% of US stocks

Operating margin
12.4%

Higher than 70% of US stocks

Net margin
−6.9%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−6.9%

Higher than 38% of US stocks

Return on assets
3.3%

Higher than 67% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TRLV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TRLVTrulieve Cannabis Corp.$1.7B
98
ALVOAlvotech$1.6B
22
ANIPANI Pharmaceuticals, Inc.$1.8B
99
PAHCPhibro Animal Health Corp.$1.5B
92
HROWHarrow, Inc.$1.4B
55
PRGOPerrigo Co. Plc$1.4B
53
AMLXAmylyx Pharmaceuticals, Inc.$2.2B
60
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TRLV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TRLV news & analysis

Best Marijuana Stocks to Add to Your August 2026 Watchlist

MarijuanaStocks · 30 July 2026neutral

A MarijuanaStocks article notes the cannabis industry continues evolving with state-level legalization expansions, and highlights that large multi-state operators are strengthening their businesses as investors focus on revenue consistency, profitability, and balance sheet health.

Why it matters — Trulieve watchers would care because as a major multi-state operator, the article's emphasis on consistent revenue, profitability, and healthy balance sheets reflects key metrics the market is using to evaluate companies like Trulieve.

FAQ

Frequently asked questions about TRLV stock

What is the TRLV stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Trulieve Cannabis Corp. have a median 12-month price target of $20, with estimates ranging from $15 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRLV stock a buy right now?

Of the 7 analysts covering Trulieve Cannabis Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Trulieve Cannabis Corp. 98 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRLV?

As at 1 Aug 2026, Trulieve Cannabis Corp. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).

Will TRLV stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +126.7% from the last close, and Ticker Nerd's factor model ranks Trulieve Cannabis Corp. 98 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRLV stock forecast for 2030?

No analyst covering Trulieve Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $21 over the next 12 months.

How has TRLV stock performed over the past year?

Trulieve Cannabis Corp. returned +83.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Trulieve Cannabis Corp. do?

Trulieve Cannabis Corp. is a vertically integrated cannabis company that focuses on the cultivation, processing, manufacturing, and retail distribution of cannabis products in the United States.

What is the latest news on TRLV?

The most recent item we track (MarijuanaStocks, 30 July 2026): "Best Marijuana Stocks to Add to Your August 2026 Watchlist". A MarijuanaStocks article notes the cannabis industry continues evolving with state-level legalization expansions, and highlights that large multi-state operators are strengthening their businesses as investors focus on revenue consistency, profitability, and balance sheet health.

Company

About Trulieve Cannabis Corp.

Trulieve Cannabis Corp. is a vertically integrated cannabis company that focuses on the cultivation, processing, manufacturing, and retail distribution of cannabis products in the United States. The company operates as a multi-state operator with established hubs in the Northeast, Southeast, and Southwest, with significant market presence in states such as Florida, Arizona, and Pennsylvania. Trulieve Cannabis Corp. manages the cannabis value chain from seed to sale, producing a wide range of medical and adult-use cannabis products, including flower, concentrates, edibles, and topicals, under its own brands. The company distributes its products through a network of branded dispensaries as well as direct-to-patient delivery services where permitted, serving medical patients and adult-use consumers under applicable state regulations. Headquartered in Tallahassee, Florida, Trulieve Cannabis Corp. plays a notable role in the regulated U.S. cannabis market by combining large-scale cultivation and manufacturing capabilities with retail operations, positioning itself as a key provider of regulated cannabis products across multiple states.

CEO Ms. Kimberly Rivers J.D. · 5,000 employees · United States · https://www.trulieve.com